Friday, July 25, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment

Simon Osuji by Simon Osuji
August 25, 2023
in Technology
0
AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

  • AHB-137 is cleared for initiation of a clinical trial in CHB patients in the US
  • AHB-137 is an unconjugated antisense oligonucleotide (ASO) aimed for functional cure of CHB

SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB) infection, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application for a clinical trial on AHB-137. The clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled study, intended to assess the safety, tolerability, pharmacokinetics, and initial efficacy of AHB-137 in CHB patients (clinicaltrials.gov # NCT05717686).

AusperBio (PRNewsfoto/AusperBio Therapeutics Inc.)

This milestone is a pivotal juncture for AusperBio.

“The FDA’s clearance of our IND application to initiate clinical evaluation of AHB-137 in CHB patients in the United States brings us one step closer to introducing a potential functional cure for people living with HBV.” said AusperBio CEO and Co-founder Dr. Guofeng Cheng, “This milestone is a pivotal juncture for AusperBio, underscoring our consistent and outstanding execution in driving innovative therapies towards a functional cure for CHB.”

“We are committed to expediting patient access to innovative treatments.” Dr. Cheng Yong Yang, CSO and Co-founder of AusperBio highlighted. “Our focus now is on working closely with key opinion leaders to initiate the CHB patient study in the US.”

About Chronic Hepatitis B

Chronic Hepatitis B (CHB) infection is a liver disease estimated to affect nearly 290 million people worldwide and can cause other chronic complications such as cirrhosis and hepatocellular carcinoma. Although current treatment options can suppress HBV replication, achieving a cure is rare. Therefore, the discovery of a cure for CHB remains an urgent need.

About AusperBio.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio’s strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.

Media Contact

Email: info@ausperbio.com

Investor Contact

Tel: 650-888-1756 (US)

Email: growth@ausperbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ausperbio-announces-fda-clearance-of-ind-application-of-ahb-137-in-chronic-hepatitis-b-treatment-301909966.html

SOURCE AusperBio Therapeutics Inc.

Source link

Related posts

Legal analysis of ICJ advisory opinion on climate change obligations – EnviroNews

Legal analysis of ICJ advisory opinion on climate change obligations – EnviroNews

July 25, 2025
SRADev inaugurates zero waste ambassadors in Lagos schools – EnviroNews

SRADev inaugurates zero waste ambassadors in Lagos schools – EnviroNews

July 25, 2025
Previous Post

PEPE Coin Falls 24% As Rug Pull Rumors Looms

Next Post

Evidence Undermines ‘Rapid Onset Gender Dysphoria’ Claims

Next Post
Evidence Undermines ‘Rapid Onset Gender Dysphoria’ Claims

Evidence Undermines 'Rapid Onset Gender Dysphoria' Claims

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Egypt pledges closer ties with South Africa on 51st Armed Forces Day celebrations

Egypt pledges closer ties with South Africa on 51st Armed Forces Day celebrations

9 months ago
Baloch Separatists Kill Eight Pakistanis in Iran

Baloch Separatists Kill Eight Pakistanis in Iran

3 months ago
Digital Finance Africa Recap: Unlocking the Future of Fintech | IT News Africa

Digital Finance Africa Recap: Unlocking the Future of Fintech | IT News Africa

2 years ago
one of the largest and most historic gardens in the US reveals its transformation

one of the largest and most historic gardens in the US reveals its transformation

8 months ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • The world’s top 10 most valuable car brands in 2025

    0 shares
    Share 0 Tweet 0
  • Top 10 African countries with the highest GDP per capita in 2025

    0 shares
    Share 0 Tweet 0
  • Tanzania’s natural gas sector goes global with Dubai deal

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.